The intersection of a worsening pediatric mental health crisis and a severe child psychiatry workforce shortage has made AI-assisted tools an appealing proposition — but a new narrative review offers a sobering corrective to the enthusiasm. Understanding where AI genuinely helps, where it falls short, and where it may cause outright harm is now a practical question for clinicians, parents, and health systems alike.
The review, published in Current Psychiatry Reports, assessed the landscape of AI applications across child and adolescent psychiatric care. The authors identified several categories: AI scribes for documentation, multimodal machine-learning diagnostic tools, AI-assisted therapeutics including robotics and virtual reality, chatbots, and robot companions. Across most domains, the verdict was consistent — development is early-stage and clinical deployment premature. AI scribes face particular structural barriers in pediatric settings, including multi-party visit dynamics and heightened consent sensitivities. Diagnostic tools relying on neuroimaging remain cost-prohibitive at scale. One notable exception was AI-enabled video and eye-tracking for autism spectrum disorder detection, which showed more tangible near-term clinical promise. For depression, chatbots and robot companions demonstrated modest benefit signals, though pediatric-specific evidence remains thin and risks of serious harm — including crisis mismanagement and unhealthy emotional attachment — were explicitly flagged.
This review arrives at a critical juncture. Algorithmic bias is a particularly underappreciated hazard in psychiatric AI: training datasets often underrepresent minority youth, meaning diagnostic or therapeutic tools may perform unevenly across the populations with the greatest unmet need. The misinformation risk from large language model-based chatbots — which can generate clinically plausible but inaccurate mental health guidance — also warrants serious attention before any broad deployment. Editorially, this review functions as a useful calibration document rather than a paradigm-shifting finding. It consolidates scattered early-phase literature and signals that the field needs rigorous, pediatric-specific randomized evidence before AI tools move from pilot programs to standard care. The eye-tracking autism application stands out as the most implementation-ready area to watch.
